Tendyne, the mitral valve replacement technology that Abbott Laboratories Inc. acquired three years ago, has potential to successfully treat patients with severe mitral regurgitation, according to early follow-up data presented May 23 at EuroPCR in Paris.
The results from a single-arm, multicentre global study to support the CE mark of Tendyne were presented at EuroPCR by principal investigator David Muller of St Vincent's Hospital, Sydney, Australia. They include the first 100 severe MR patients implanted with the device, of whom 90 were followed up at 30 days. The mean age of the patient sample was 75
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?